Thursday morning’s pre-market activity paved the way for dynamic and action packed trading for GNCA, GENOCEA BIOSCIENCES, INC. Beginning with the 8-k filing from the organization indicating that the company will present the “ to certain investors regarding the efficacy data from the twelve-month analysis of the Company’s Phase 2 dose optimization trial evaluating the immunotherapy GEN-003 for the treatment of genital herpes”. In the presentation, the company showed that GEN-003 shows sustained reduction of viral shedding rate. The information propelled positive price action and volatility over 40% in pre-market trading.
Throughout the day, GNCA was highlighted by the TradeXchange Analyst desk and contributors. Early morning technical levels were brought to the attention by ZOZO-LevelWatch. The day’s price action was further influenced by the detection of positive commentary by analysts. The combination of important analyst notes, volume interest, and price action proved to be a boon for the day’s activity.
The afternoon trading in GNCA provided greater price action with more detection of positive analyst commentary and important technical levels. The last two hours of trading in the regular session showed a further price gain of $2.
